|1.||Wolfenstein-Todel, Carlota: 2 articles (05/2007 - 03/2003)|
|2.||Ingham, Randall R: 1 article (07/2014)|
|3.||Dalia, Samir: 1 article (07/2014)|
|4.||Sweeney, Joseph D: 1 article (07/2014)|
|5.||Reagan, John L: 1 article (07/2014)|
|6.||Butera, James N: 1 article (07/2014)|
|7.||Troncoso, María F: 1 article (05/2007)|
|8.||Longhi, Silvia A: 1 article (05/2007)|
|9.||Biron, Verónica A: 1 article (05/2007)|
|10.||Retegui, Lilia A: 1 article (05/2007)|
07/01/2014 - "Bleeding was observed to occur early during the hospital course at a median of 2-3 days after initiation of the pDTI. "
07/01/2014 - "Patients in period 2 were treated with pDTI therapy for a median of 5 days less (p<0.0001) however the incidence of Grade III and IV bleeding episodes was not different. "
07/01/2014 - "Implementation of the IgG class HIT EIA resulted in a decrease in the number of days on a pDTI and a decrease in the average pDTI acquisition cost per patient without an observed change in serious bleeding events."
07/01/2014 - "To determine whether the HIT IgG class platelet factor 4 (PF4) enzyme immunoabsorbant assay (EIA) influenced the duration of parenteral direct thrombin inhibitor (pDTI) therapy or bleeding risk in patients started on pDTI for a presumed diagnosis of HIT. "
|3.||Platelet Factor 4
|4.||Immunoglobulin G (IgG)
|5.||DNA (Deoxyribonucleic Acid)